Clinical Trial Update: A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating SHR-1826 injections in patients with non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SHR-1826

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: NSCLC | Phase 2 | Status: RECRUITING